Ariprazol® Receives Qualification Release in the EU and Launches Sales in Latvia
Acino, part of Arcera, has obtained a qualification release for its prescription antipsychotic medicine Ariprazol® (aripiprazole) in the European Union, with initial commercial activities starting in Latvia. The product meets European quality standards and has been included in Latvia’s reimbursement program, enabling faster patient access.
The launch in the EU represents a significant step forward for Acino’s Ukrainian manufacturing operations and highlights the company’s ongoing efforts to support Ukraine’s pharmaceutical sector and national exports.
“This project exemplifies the strong teamwork within Arcera. Its successful launch demonstrates how our internal collaboration empowers us to achieve our goals, even in challenging times,” said Maryna Afanasieva, Head of Innovation and Business Development at Acino Ukraine.
“The EU release is a strategically important milestone for Acino in Ukraine. It is a testament to the quality of Ukrainian manufacturing and our continued efforts to enhance production capabilities and facilitate international distribution of medicines. With this move, we expand the company’s presence in the European Union and strengthen Ukraine’s economic potential,” said Eugene Zaika, Regional Director of Acino Ukraine.
About the Product
Ariprazol® (aripiprazole) is an antipsychotic medication in the neuroleptic class, indicated for the treatment of schizophrenia and bipolar disorder in adults. It is considered part of a newer generation of antipsychotic treatments and may be used as part of a broader therapeutic approach for post-traumatic stress disorder, as determined by a physician and with appropriate psychotherapeutic support.
About Acino, part of Arcera
Acino is among the top three pharmaceutical companies in Ukraine. Founded in Switzerland, Acino is part of Arcera Life Sciences, a global life sciences company headquartered in Abu Dhabi, UAE. We develop, manufacture, and commercialize a broad portfolio of innovative and proven medicines across key international markets. With a large footprint reaching patients in over 120 markets, and manufacturing and packaging facilities in eight countries, we offer more than 2,000 medicines across various therapeutic areas worldwide.